Introduction & Objective:GLP-1 agonist (GLP-1) therapy improves metabolic measures (MetM) in youth with type 2 diabetes. Little is known about the effects of GLP-1 use in adolescents and young adults (AYA) with type 1 diabetes (T1D). Our objective was to determine whether GLP-1 therapy improved MetM in AYA with T1D and elevated BMI.
Methods: We conducted a retrospective chart review of all AYA with T1D prescribed a GLP-1 over a 2-year period (2021-23) at our center. Nine of 16 AYAs with T1D and elevated BMI prescribed a GLP-1 had started treatment. Demographic and clinical information were recorded at baseline and the most recent visits. The % change from baseline for each MetM was calculated for each AYA individually and the group.
Results: GLP-1s used included liraglutide, semaglutide, and tirzepatide. Baseline cohort (n=9) was 66.7% female, race: 7 NHW, 1 NHB, 1 multiracial, 78% privately insured, 100% used CSII and CGM; median (IQR) age 17.8 years (15.5, 20.3), T1D duration 10.9 years (9,11), HbA1c 7.3% (7.2, 8.4), BMI 30.3 kg/m2 (28.6, 31.7), and weight 81.1 kg, (77.3, 90.8). Median treatment time was 10 months (6, 12). GLP-1s were well tolerated (33% GI complaints) and most AYAs had improved MetM across all domains (Figure 1).
Conclusion: GLP-1 use among AYA with T1D was well-tolerated and associated with improved metabolic measures in a real-world setting. Randomized controlled trials assessing long-term clinical efficacy are warranted.
N. Shacham: None. J. Ilkowitz: None. C.R. Stein: None. M. Gallagher: None.
